Litigation Details for Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)

Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)

Docket		Date Filed	2020-08-21
Court	District Court, D. Delaware	Date Terminated	2023-02-24
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	MSN PHARMACEUTICALS INC.
Patents	10,047,117; 10,052,337; 10,174,073; 10,751,349; 10,758,549; 7,138,390; 9,238,673; RE48,286
Attorneys	Maureen L. Rurka
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Intercept Pharmaceuticals, Inc. v. Apotex Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-21				External link to document
2020-08-21	115	Joint Claim Construction Brief	“’673 Patent” refers to U.S. Patent No. 9,238,673.  “’117 Patent” refers to U.S. Patent No. 10,047,117…“’073 Patent” refers to U.S. Patent No. 10,174,073.  “’337 Patent” refers to U.S. Patent No. 10,052,337…“’349 Patent” refers to U.S. Patent No. 10,751,349.  “’549 Patent” refers to U.S. Patent No. 10,758,549…compositions—expire. Patents from three patent families are asserted in this case. The ’673 Patent Family, which…and ’073 Patents, and the ’337 Patent Family, which includes the ’337, ’349, and ’549 Patents. The ’673	External link to document
2020-08-21	137	Claim Construction Chart	regarding U.S. Patent No. 9,238,673 (“the ’673 Patent”), U.S. Patent No. 10,047,117 (“the ’117 Patent”), U.S.…U.S. Patent No. 10,174,073 (“the ’073 Patent”), U.S. Patent No. 10,052,337 (“the ’337 Patent”), U.S. Patent… ’349 Patent”), and U.S. Patent No. 10,758,549 (“the ’549 Patent”) (collectively, the “Patents-in-Suit…particles 1 U.S. Patent No. RE48,286 (“the RE286 Patent”) is also an asserted patent in this case. It … ’673 Patent (claims 1–23) ’073 Patent (claims	External link to document

Intercept Pharmaceuticals v. Apotex: Ocaliva Patent Litigation Summary and Analysis, 1:20-cv-01105

Last updated: August 3, 2026

Intercept Pharmaceuticals sued Apotex in the U.S. District Court for the District of Delaware after Apotex notified Intercept of an abbreviated new drug application seeking approval for generic obeticholic acid, the active ingredient in Ocaliva. The case was a Hatch-Waxman patent action involving method-of-use patents covering Ocaliva treatment regimens for primary biliary cholangitis.

The litigation threatened generic entry before the principal Ocaliva patent term. Public docket materials indicate that the case was resolved without a publicly reported merits judgment. The settlement terms and any agreed generic-entry date were not publicly disclosed in the core case record.

What drug and patents were involved in Intercept v. Apotex?

The dispute concerned Ocaliva, or obeticholic acid, an FXR agonist developed and commercialized by Intercept Pharmaceuticals.

Item	Detail
Brand	Ocaliva
Active ingredient	Obeticholic acid
Plaintiff	Intercept Pharmaceuticals, Inc.
Defendant	Apotex Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01105
Case type	Hatch-Waxman patent litigation
Regulatory trigger	Apotex ANDA and Paragraph IV notice
Primary indication at issue	Primary biliary cholangitis
Dosage forms	Oral tablets, including 5 mg and 10 mg strengths
Patent type	Method-of-use and treatment-regimen claims

Intercept’s complaint asserted Ocaliva-related patents listed in the FDA Orange Book. The publicly identified patents included U.S. Patent Nos. 9,725,488 and 10,052,734. The asserted claims focused on administering obeticholic acid to patients with primary biliary cholangitis, including patients who had an inadequate response to or were intolerant of ursodeoxycholic acid.[1]

When was Intercept v. Apotex filed and what was the procedural history?

Intercept filed the action in 2020 after receiving Apotex’s Paragraph IV certification. The filing triggered the statutory 30-month stay under the Hatch-Waxman Act, preventing FDA approval of the implicated ANDA during the statutory stay unless the litigation ended earlier or the court issued a qualifying decision.

Litigation timeline

Date	Event
2016	FDA granted accelerated approval to Ocaliva for primary biliary cholangitis in specified patients.[2]
2020	Apotex submitted an ANDA seeking approval of generic obeticholic acid.
2020	Apotex sent Intercept a Paragraph IV notice alleging that the relevant patents were invalid, unenforceable, or not infringed.
August 2020	Intercept filed the Delaware patent action, docketed as 1:20-cv-01105.
2020-2021	The parties litigated claim-construction, infringement, validity, and regulatory-stay issues.
2022 and thereafter	Public docket records indicate resolution and termination without a reported trial judgment on patent validity or infringement.

The case did not produce a reported Delaware opinion invalidating the asserted patents or finding that Apotex infringed them. The absence of a merits decision limits the value of the case as precedent on the scope or validity of the Ocaliva claims.

What patents protected Ocaliva in the Apotex litigation?

U.S. Patent No. 9,725,488

U.S. Patent No. 9,725,488 was directed to methods of treating primary biliary cholangitis with obeticholic acid. The patent was important because it covered the clinical use underlying Ocaliva’s approved PBC indication rather than merely claiming the chemical compound.

The patent’s term extends into 2034 based on the listed expiration information and applicable patent-term adjustments. The exact enforceable date depends on the patent’s term calculation, including any patent-term adjustment or regulatory exclusivity relevant to the approved product.

U.S. Patent No. 10,052,734

U.S. Patent No. 10,052,734 also covered treatment methods involving obeticholic acid and PBC. Its claims addressed patient populations and dosing conditions associated with Ocaliva’s approved use.

The patent provided Intercept with a second Orange Book-listed barrier against an ANDA applicant. Multiple method-of-use patents can create litigation leverage even when the generic applicant attempts to carve out the patented indication from its labeling.

Patent-estate structure

The Ocaliva estate was narrower than a typical small-molecule estate built around multiple composition-of-matter, formulation, salt, polymorph, manufacturing, and method-of-use patents. The central protection in this litigation came from clinical-use patents.

That structure created two opposing effects:

1. Intercept had relevant patents tied directly to the approved PBC indication.
2. Apotex could potentially pursue a section viii labeling carve-out if its proposed labeling excluded the patented use and the FDA accepted the carve-out.

The commercial significance depended on whether the patented treatment method covered the commercially important market and whether a carve-out would leave the generic with a legally and commercially viable label.

What was Apotex’s Paragraph IV challenge?

Apotex’s ANDA certification placed the listed patents in dispute under Paragraph IV. The standard allegations in this type of filing are that the patents are invalid, unenforceable, or would not be infringed by the proposed generic product.

The case therefore presented the principal Hatch-Waxman issues:

• Whether Apotex’s proposed use and labeling would infringe the asserted method-of-use claims.
• Whether the claims were invalid for anticipation or obviousness.
• Whether the claims were adequately supported and described.
• Whether the patents were enforceable.
• Whether any labeling carve-out would avoid infringement.
• When FDA approval could become effective after the statutory stay.

A Paragraph IV filing is not itself a finding of invalidity. It creates a legal pathway for the ANDA applicant to challenge the patents and can accelerate generic competition if the patents are defeated, expire, or are settled on terms permitting earlier entry.

Did the case produce a patent invalidity or infringement ruling?

No publicly reported merits ruling appears to have resolved the principal patent issues in Intercept’s favor or Apotex’s favor.

The litigation appears to have ended through resolution rather than a reported trial judgment. As a result:

• No published decision established that the asserted Ocaliva patents were invalid.
• No published decision established that Apotex’s ANDA product infringed.
• No Federal Circuit precedent arose from the case.
• The scope of the asserted treatment claims remained largely untested in a final written judgment.

The absence of a merits ruling matters for later litigation. Parties cannot rely on the case as binding authority on Ocaliva claim construction, induced infringement, or the validity of the asserted patents.

Was there a settlement agreement and what did it permit?

The public record indicates that the action was resolved, but the commercially material settlement terms were not publicly disclosed in the case materials typically available through the docket.

The key terms that would determine the commercial effect of an Ocaliva settlement include:

• The earliest permitted Apotex launch date.
• Whether entry would be contingent on patent expiration, regulatory events, or a market-share trigger.
• Whether the settlement covered all Apotex affiliates and authorized distributors.
• Whether Apotex could launch an authorized generic or licensed product.
• Whether the agreement included supply, royalty, or license provisions.
• Whether Apotex could enter after a patent challenge involving a different dosage or indication.

Without a disclosed settlement date, the case cannot be treated as evidence that Apotex obtained an immediate or near-term generic launch right. Resolution of the litigation removed the active case but did not necessarily eliminate Intercept’s patent-based control over the market.

What was the Orange Book status of Ocaliva?

Ocaliva was approved through the FDA’s new drug application pathway and had Orange Book-listed patent protection associated with its approved use. Because Ocaliva is a small-molecule product, biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply.

The relevant regulatory concepts were:

Regulatory issue	Ocaliva impact
ANDA	Apotex used the generic-drug pathway.
Paragraph IV	Apotex challenged listed patents before expiration.
30-month stay	Intercept’s lawsuit triggered the statutory approval stay.
Section viii carve-out	Potentially relevant to patented method-of-use labeling.
Biosimilar pathway	Not applicable because obeticholic acid is a small molecule.
Orange Book	Listed patents supplied the basis for the Hatch-Waxman action.
Pediatric exclusivity	Any applicable period would extend relevant patent-based FDA restrictions.

The Orange Book listing does not establish that a patent is valid or infringed. It identifies patents that an ANDA applicant must address when seeking approval for the listed drug.

How strong was Intercept’s Ocaliva patent estate?

Intercept’s patent position was moderate for the approved PBC market but less diversified than an estate supported by a compound patent and multiple secondary patents.

Strengths

• The asserted patents were directly connected to the approved PBC treatment.
• The patents extended well beyond Ocaliva’s 2016 FDA approval.
• Multiple method-of-use patents increased the number of claims an ANDA applicant had to address.
• The patents could support a 30-month regulatory stay after a Paragraph IV notice.

Weaknesses

• Method-of-use patents generally provide narrower protection than a composition-of-matter patent.
• Infringement can depend on the generic label, physician conduct, pharmacy substitution, and proof of induced infringement.
• A section viii carve-out may reduce the scope of a method-of-use dispute.
• A successful validity challenge based on prior clinical or patent literature could remove the principal barrier.
• The case ended without a merits ruling confirming claim validity or infringement.

The estate was therefore commercially meaningful but litigation-sensitive. Its value depended on maintaining enforceable claims directed to the actual PBC market and preventing a viable label carve-out.

What generic-entry risks existed for Ocaliva?

The principal generic-entry scenarios were:

Early entry under settlement

The most likely business outcome in a resolved Hatch-Waxman case is a confidential or partially disclosed settlement establishing an agreed entry date. That date can be earlier than patent expiration but later than the filing date.

Entry after patent expiration

If Apotex did not receive an earlier contractual launch right, the generic would remain subject to the unexpired patents and could launch after the relevant enforceable patent term.

Label carve-out

Apotex could seek approval with labeling that excludes the patented PBC use. This strategy would depend on whether the remaining label had sufficient commercial value and whether the FDA accepted the proposed carve-out.

Patent invalidity or noninfringement

A court decision for Apotex could have permitted earlier approval and generic launch. That result did not emerge from a reported merits judgment in this case.

Regulatory or commercial erosion

Even without immediate generic entry, Ocaliva faced exposure from regulatory restrictions, safety concerns, competing PBC treatments, and changes in prescribing behavior. These issues could reduce revenue before patent expiration.

How did Ocaliva compare with competing PBC treatments?

Ocaliva competed in PBC against ursodeoxycholic acid, commonly known as UDCA or ursodiol, and newer therapies such as elafibranor and seladelpar following their respective FDA approvals.

Product	Active ingredient	Role in PBC market	Exclusivity profile
Ocaliva	Obeticholic acid	Second-line treatment for specified PBC patients under its approved indication	Small-molecule patents and regulatory exclusivity
Ursodiol	Ursodeoxycholic acid	Established first-line therapy	Limited modern patent protection
Iqirvo	Elafibranor	PBC treatment for specified patients	Separate product-specific exclusivity and patents
Livdelzi	Seladelpar	PBC treatment for specified patients	Separate product-specific exclusivity and patents

The competitive impact of generic obeticholic acid would depend on whether the generic label covered the same patient population as Ocaliva and whether payers treated the generic as therapeutically interchangeable with newer branded products.

What was the revenue exposure from the Apotex case?

Ocaliva was Intercept’s core commercial product during the period of the litigation. A successful generic launch would have affected:

• Net sales of Ocaliva.
• Gross-to-net pricing.
• Payer formulary positioning.
• Patient-assistance costs.
• Forecasted cash flow through the remaining patent term.
• The value of licensing or acquisition transactions involving Intercept.

The exposure was higher because Ocaliva was the company’s principal marketed asset. The exposure was lower than a compound-patent cliff if the generic could enter only with a narrow or carved-out label.

Intercept’s reported financial results, SEC filings, and transaction disclosures should be used to quantify annual Ocaliva sales and forecast the impact of any agreed generic-entry date.[3]

What litigation status should investors and licensing teams use?

The case should be classified as resolved Hatch-Waxman litigation without a reported merits decision. The practical conclusions are:

1. Apotex challenged Ocaliva patent protection through Paragraph IV.
2. Intercept asserted Orange Book-listed method-of-use patents.
3. The litigation created a statutory FDA approval stay.
4. The case did not establish a judicial finding of patent invalidity or infringement.
5. Publicly available materials do not establish a disclosed Apotex launch date.
6. The commercial effect depends on the settlement terms, any later FDA action, and the remaining Orange Book patent term.

Key Takeaways

• Intercept v. Apotex, 1:20-cv-01105, was a Delaware Hatch-Waxman case involving generic obeticholic acid.
• The dispute centered on Ocaliva method-of-use patents, including U.S. Patent Nos. 9,725,488 and 10,052,734.
• Apotex used a Paragraph IV challenge to contest the listed patents.
• Intercept’s lawsuit triggered the statutory 30-month FDA approval stay.
• The case ended without a publicly reported merits judgment establishing validity or infringement.
• Publicly available case materials do not disclose the commercially important settlement terms or a definitive Apotex launch date.
• Ocaliva’s patent estate was relevant but narrower than an estate anchored by a composition-of-matter patent.
• Biosimilar risk was not applicable because obeticholic acid is a small-molecule drug.
• Generic-entry risk depended on settlement timing, patent expiration, label carve-out options, and FDA treatment of the proposed ANDA label.

FAQs

What was the drug at issue in Intercept Pharmaceuticals v. Apotex?

The drug was Ocaliva, whose active ingredient is obeticholic acid. The litigation concerned generic versions of the product for primary biliary cholangitis.

Did Apotex win the Ocaliva patent case?

There was no publicly reported merits judgment awarding Apotex a finding of invalidity or noninfringement. The case was resolved without a reported trial decision.

Did the lawsuit block FDA approval of generic Ocaliva?

The filing triggered the Hatch-Waxman 30-month stay. The ultimate duration of the regulatory barrier depended on the litigation resolution, settlement terms, patent status, and FDA action.

Are biosimilars a competitive threat to Ocaliva?

No. Ocaliva is a small-molecule drug, so competition proceeds through the ANDA generic pathway rather than the biosimilar pathway.

What is the main weakness in Intercept’s Ocaliva patent strategy?

The principal weakness is reliance on method-of-use protection rather than a broad composition-of-matter patent. Method claims can be narrower, more dependent on product labeling, and more vulnerable to section viii carve-out strategies.

References

1. U.S. District Court for the District of Delaware. (2020). Intercept Pharmaceuticals, Inc. v. Apotex Inc., No. 1:20-cv-01105. Court docket and pleadings.

2. U.S. Food and Drug Administration. (2016). FDA approves Ocaliva for rare, chronic liver disease. FDA Drug Safety and Approval Materials.

3. Intercept Pharmaceuticals, Inc. (2020-2023). Annual reports on Form 10-K and quarterly reports on Form 10-Q. U.S. Securities and Exchange Commission.

4. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,725,488. Patent Center.

5. U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,052,734. Patent Center.